چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده | نفر چندم مقاله |
|---|---|
| فاطمه جعفرلو | اول |
| ثمین شیبافر | دوم |
| عنوان | متن |
|---|---|
| خلاصه مقاله | Introduction: Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system that can involve the auditory pathways, leading to sensorineural hearing loss in a subset of patients. Although hearing loss is not among the most common clinical manifestations of MS, it may significantly impact patients’ quality of life. Disease-modifying therapies (DMTs), primarily targeting immune-mediated inflammation, have shown varying effects on auditory dysfunction associated with MS. This review aims to summarize the current evidence on the impact of MS pharmacological treatments on hearing loss and auditory function in patients with MS. Method and materials: A comprehensive review of the literature was conducted using PubMed, Scopus, and Web of Science databases using the keywords Multiple sclerosis, Hearing loss, Disease-modifying therapies, Corticosteroids, and Auditory dysfunction. Studies published in English between 2000 and 2025 were included. Relevant studies, including clinical trials, observational studies, and case reports, were analyzed to evaluate the effects of interferons, glatiramer acetate, monoclonal antibodies, and oral DMTs on MS-related hearing loss. Results: Evidence suggests that some MS patients experience improvement in auditory function following initiation of DMTs, particularly with agents that effectively reduce inflammatory activity such as corticosteroids, natalizumab, and ocrelizumab. Interferon-based therapies and glatiramer acetate show limited direct impact on hearing recovery but may prevent further auditory deterioration by reducing relapse frequency. Reports indicate that acute MS-related hearing loss often responds to high-dose corticosteroid therapy, while long-term stabilization may be achieved through maintenance DMTs. Conclusion: Current findings indicate that MS pharmacotherapies may contribute to the stabilization and, in some cases, improvement of hearing loss in affected patients, mainly by reducing demyelinating activity in auditory pathways. Nonetheless, the evidence is largely indirect and based on small sample sizes. Further targeted research is needed to clarify the role of DMTs in managing MS-related auditory dysfunction. |
| کلمات کلیدی | Multiple sclerosis, Hearing loss, Disease-modifying therapies, Corticosteroids, Auditory dysfunction |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| poster 3 certificate.pdf | 1404/09/30 | 528581 | دانلود |
| congress booklet.pdf | 1404/09/30 | 1687713 | دانلود |
